Generated by AI
Entera Bio Ltd. is a clinical-stage biopharmaceutical company focused on developing orally delivered peptide and protein replacement therapies for serious unmet medical needs. Its work centers on converting complex therapies that are typically injected into mini-tablet formats designed for easier administration and improved patient adherence. The company’s technology platform supports oral delivery by stabilizing peptides in the gastrointestinal tract and enhancing absorption into the bloodstream. Entera Bio’s current pipeline includes programs targeting bone, endocrine, and metabolic disorders, with research spanning parathyroid hormone, GLP-1, and GLP-2-based therapies. The company also pursues collaborations and licensing opportunities to advance its oral drug delivery platform across selected therapeutic areas. Headquartered in Jerusalem, Israel, Entera Bio plays a specialized role in the biopharmaceutical market by addressing delivery challenges that limit the use of large-molecule medicines.
WebsiteKiryat Hadassah Minrav Building
Jerusalem, 9112002
Israel
The latest articles about ENTX.
Summary of Jul 28's posts. Generated by AI.
Summary of Jul 27's posts. Generated by AI.
Summary of Jul 28's posts. Generated by AI.
Investors talking about ENTX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.